


About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



This is a guide to the publications Spherix will produce in 2025. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications		
MARKET DYNAMIX	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.	
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.	
LAUNCH DYNAMIX	Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.	
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions.	
SPECIAL TOPI	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.	
F	and the share of a contract of a many strate	

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



2025 Dermatology Publications



Atopic Dermatitis

MARKET DYNAMIX	Atopic Dermatitis, US
REALTIME DYNAMIX	Atopic Dermatitis, EU5Atopic Dermatitis, JP/ CH
LAUNCH DYNAMIX	 Ebglyss (Eli Lilly) in Atopic Dermatitis, US Nemluvio (Galderma) in Atopic Dermatitis, US Vtama and Zoryve (Arcutis/ Dermavant) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	• Atopic Dermatitis, US

Alopecia Areata		
	• Alopecia Areata, US	
LAUNCH DYNAMIX	 Leqselvi (SUN Pharma) in Alopecia Areata, US Litfulo (Pfizer) in Alopecia Areata, US 	

Hidradenitis Suppurativa

MARKET DYNAMIX	Hidradenitis Suppurativa, US
REALTIME DYNAMIX	• Hidradenitis Suppurativa, EU5
	 Bimzelx (UCB) in Hidradenitis Suppurativa, US* Cosentyx (Novartis) in Hidradenitis Suppurativa, US

Dermatology Related Respiratory

MARKET DYNAMIX Asthma, USChronic Spontaneous Urticaria, US

REALTIME DYNAMIX	Plaque Psoriasis, USPlaque Psoriasis, EU5			
LAUNCH DYNAMIX	• Bimzelx (UCB) in Plaque Psoriasis, US			
PATIENT CHA DYNAMIX	• Plaque Psoriasis, US			
SPECIAL TOPIX	• The Oral Opportunity in Plaque Psoriasis, US			

Plaque Psoriasis

Other Dermatology Indications		
MARKET DYNAML	Prurigo Nodularis, USVitiligo, US	
LAUNCH DYNAMIX	 Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria, US Dupixent (Sanofi/Regeneron) in Chronic Obstructive Pulmonary Disease, US Remibrutinib (Novartis) in Chronic Spontaneous Urticaria, US Nemluvio (Galderma) in Prurigo Nodularis, US 	
SPECIAL TOPI/	 Biologic Coordinators Across Dermatology, US Awareness and Expected Impact of IRA Changes in 2025 	

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
ø	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
—	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas

2025 Gastroenterology Publications



	Eosinophilic Esophagitis		: Dysfunction-associated Steatotic Liver Disease / bolic Dysfunction-associated Steatohepatitis
MARKET DYNAMI	Eosinophilic Esophagitis, USEosinophilic Esophagitis, EU5	MARKET DYNAMIX	• MASLD/MASH, US
	• Eohilia (Takeda) in Eosinophilic Esophagitis, US	LAUNCH DYNAMIX	 Rezdiffra (Madrigal) in MASLD/MASH, US Wegovy (Novo Nordisk) in MASLD/MASH, US*
		PATIENT CHART DYNAMI	• MASLD/MASH, US
In	flammatory Bowel Disease		
REALTIME DYNAMI/	 Crohn's Disease, US Crohn's Disease, EU5 Ulcerative Colitis, US Ulcerative Colitis, EU5 	MARKET DYNAMI	 Celiac Disease, US Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US
	 Entyvio SC (Takeda) in Crohn's Disease, US Tremfya (Janssen) in Crohn's Disease, US 	REALTIME DYNAMIX	Irritable Bowel Syndrome, US
LAUNCH DYNAMIX	 Omvoh (Eli Lilly) in Crohn's Disease, US Entyvio SC (Takeda) in Ulcerative Colitis, US Omvoh (Eli Lilly) in Ulcerative Colitis, US Skyrizi (AbbVie) in Ulcerative Colitis, US Tremfya (Janssen) in Ulcerative Colitis, US Velsipity (Pfizer) in Ulcerative Colitis, US 	LAUNCH DYNAMI	 Iqirvo (Ipsen) in Primary Biliary Cholangitis, US Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US
		SPECIAL TOPI/	 MASH Screening and Management among PCPs and Endocrinologists, US Biologic Coordinators in Gastroenterology, US
	Inflammatory Bowel Disease New Starts, US		Awareness and Expected Impact of IRA Changes in 2025
PATIENT CHART DYNAMI	 Inflammatory Bowel Disease Switching, US Inflammatory Bowel Disease Switching, EU5 		MARKET DYNAMIX Yearly market overview of key indication
		R	EALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates
		Key	LAUNCH DYNAMIX Monthly benchmark of newly launched products
		PATIEN	NT CHART DYNAMIX Yearly review of large-scale patient chart audits

SPECIAL TOPIX Current events on specific interest areas

2025 Rheumatology Publications



	Ankylosing Spondylitis & liographic Axial Spondyloarthritis		Other Rheumatology Indications
MARKET DYNAMI/• Ankylosing Spondylitis & nr-AxSpA, US • Ankylosing Spondylitis & nr-AxSpA, EU5LAUNCH DYNAMI/• Bimzelx (UCB) in Ankylosing Spondylitis & nr- 		 Dermatomyositis, US (2024) Giant Cell Arteritis, US (2024) Idiopathic Inflammatory Myopathy, US Polymyalgia Rheumatica, US (2024) Rheumatoid Arthritis, US Rheumatoid Arthritis, EU5 	 Giant Cell Arteritis, US (2024) Idiopathic Inflammatory Myopathy, US Polymyalgia Rheumatica, US (2024) Rheumatoid Arthritis, US Rheumatoid Arthritis, EU5
	Lupus		 Sjogren's Syndrome, US Systemic Sclerosis, US Systemic Sclerosis, EU5 (2024)
MARKET DYNAMI	 Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus, EU5 Cutaneous Lupus Erythematosus, US 	LAUNCH DYNAMIX	 Hizentra (CSL) in Dermatomyositis, US* Rinvoq (AbbVie) in Giant Cell Arteritis, US*
REALTIME DYNAMIX	 Lupus Nephritis, US Lupus Nephritis, EU5 	SPECIAL TOPI	 Cell Therapy in Rheumatology, US Feedback from ACR Convergence, US Interstitial Lung Disease in Rheumatology, US
LAUNCH DYNAMI	• Gazyva (Genentech) in Lupus Nephritis, US*		• Awareness and Expected Impact of IRA Changes in 2025
PATIENT CHART DYNAMIX	 Lupus Nephritis, US Moderate to Severe SLE, US Moderate to Severe SLE, EU5 		
	Psoriatic Arthritis		
MARKET DYNAMI	• Psoriatic Arthritis, EU5		
REALTIME DYNAMIX	Psoriatic Arthritis, US		MARKET DYNAMIX Yearly market overview of key indication
	 Bimzelx (UCB) in Psoriatic Arthritis, US Sotyktu (BMS) in Psoriatic Arthritis, US* 	(e v	REALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates LAUNCH DYNAMIX Monthly benchmark of newly launched products

PATIENT CHART DYNAMIX • Psoriatic Arthritis, US

PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas





Kidney Disease

MARKET DYNAMI	 Autosomal Dominant Polycystic Kidney Disease, US CKD& DKD, Cross-Specialty Perspective, US 	
REALTIME DYNAMIX	 Hyperkalemia, US Dialysis, US Dialysis, Renal Dietitians, US Dialysis, EU5 	
LAUNCH DYNAMI	 Xphozah (Ardelyx) in Hyperphosphatemia, US Xphozah (Ardelyx) in Hyperphosphatemia, Renal Dietitians, US Jesduvroq (GSK) in Renal Anemia, US Vafseo (Akebia) in Renal Anemia, US OLC (Unicycive) in Hyperphosphatemia, US* 	
PATIENT CHART DYNAMIX	 Chronic Kidney Disease, Non-Dialysis, Nephrology, US Dialysis, US 	
SPECIAL TOPIX	 Hypertension in CKD, US Implications of the Dialysis Bundle (US) ASN Kidney Week Conference, US Buy and Bill in Nephrology Practices, US Awareness and Expected Impact of IRA Changes in 2025, US 	
Lupus Nephritis		

Glomerular Diseases

MARKET DYNAMI/	 Complement 3 Glomerulopathy, US Focal Segmental Glomerulosclerosis, US Membranous Nephropathy, US
REALTIME DYNAMIX	IgA Nephropathy, USIgA Nephropathy, EU5
LAUNCH DYNAMI	 Fabhalta (Novartis) in IgAN, US Vanrafia (Novartis) in IgAN, US Sibeprenlimab (Otsuka) in IgAN, US* Fabhalta (Novartis) in C3G, US Empaveli (Apellis) in C3G, US*
PATIENT CHART DYNAMIX	 Complement 3 Glomerulopathy, US Focal Segmental Glomerulosclerosis, US IgA Nephropathy, US IgA Nephropathy, EU5 IgA Nephropathy, Japan IgA Nephropathy, China
PATIENT DYNAMIX	• IgA Nephropathy, US

Lupus Nephritis				
		MARKET DYNAMIX	Yearly market overview of key indication	
Lupus Nephritis, US		REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates	
• Lupus Nephritis, EU5	e	LAUNCH DYNAMIX	Monthly benchmark of newly launched products	
• Lupus Nephritis, US		PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits	
		SPECIAL TOPIX	Current events on specific interest areas	

REALTIME DYNAMIX

PATIENT CHART DYNAMIX





	Alzheimer's Disease		Multiple Sclerosis
MARKET DYNAMIX	 Alzheimer's Disease, US: Focus on Diagnostic Pathway (Q2) Alzheimer's Disease, US: Focus on Pipeline (Q4) 	MARKET DYNAMI	 Multiple Sclerosis, US: Focus on Current Market Landscape (Q1) Multiple Sclerosis, US: Focus on Pipeline Opportunities
	 Leqembi (Eisai/Biogen) in Alzheimer's Disease, US Kisunla (Eli Lilly) in Alzheimer's Disease, US 	REALTIME DYNAMIX	(Q3) • Multiple Sclerosis, Canada
PATIENT CHART DYNAMI./	Alzheimer's Disease, US		• Ocrevus Zunovo (Genentech) in Multiple Sclerosis, US
Ge	neralized Myasthenia Gravis		
REALTIME	Generalized Myasthenia Gravis, US		Other Neurology Indications
DYNAMIX	Generalized Myasthenia Gravis, EU5	MARKET	• Chronic Inflammatory Demyelinating Polyneuropathy, US
LAUNCH DYNAMIX			Epilepsy, USParkinson's Disease, US
	 SC Biologics in Generalized Myasthenia Gravis, US Uplizna in Generalized Myasthenia Gravis, US* 	SPECIAL TOPIX	Neurology Pipeline Opportunities, USPractice Dynamix in Neurology, US
PATIENT CHART DYNAMI	• General Myasthenia Gravis, US		


	Migraine
REALTIME DYNAMI	• Migraine, US
LAUNCH DYNAMIX	• Zavzpret (Pfizer) in Acute Migraine, US

SPECIAL TOPIX Current events on specific interest areas





	Diabetic Macular Edema	Othe	er Ophthalmology Indications
	• Diabetic Macular Edema, US	MARKET	Geographic Atrophy, USGlaucoma, US
LAUNCH DYNAMIX	• Pavblu in Diabetic Macular Edema, US	DYNAMIX	 Thyroid Eye Disease (TED), US
PATIENT CHART DYNAMI	• Diabetic Macular Edema, US	LAUNCH DYNAMIX	• Pavblu in Diabetic Retinopathy, US
	Neovascular Age-Related Macular Degeneration	SPECIAL TOPI/	 Gene Therapies in Retina, US Pipeline Opportunities in Ophthalmology, US
REALTIME DYNAMIX	 Neovascular Age-Related Macular Degeneration, US 		
LAUNCH DYNAMIX	 Pavblu in Neovascular Age-Related Macular Degeneration, US 		
PATIENT CHART DYNAMI	 Neovascular Age-Related Macular Degeneration, US 		





Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMI/	• Paroxysmal Nocturnal Hemoglobinuria, EU5
REALTIME DYNAMIX	• Paroxysmal Nocturnal Hemoglobinuria, US
PATIENT CHART DYNAMI.	• Paroxysmal Nocturnal Hemoglobinuria, US

Hemoglobinopathies -Sickle Cell Disease and Thalassemia

MARKET DYNAMI	Sickle Cell Disease, USThalassemia, US
LAUNCH DYNAMIX	 Casgevy and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia, US
PATIENT CHART DYNAMIX	Sickle Cell Disease, USThalassemia, US

Other Benign Hematology Indications

MARKET	 Cold Agglutin Disease (CAD) Graft vs. Host Disease (GvHD) Thrombocytopenia (Including ITP and TTP) Warm Autoimmune Hemolytic Anemia
DYNAMI/	(w-AIHA)
SPECIAL	 Adoption and Impact of Gene Therapy in
TOPIX	Hematology Multi-Specialty Approach to aHUS

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
e	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
—	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas

	Blood Clotting Disorders
MARKET DYNAMIX	Hemophilia, USHemophilia, EU5
	 Hympavzi in Hemophilia A & B Alhemo in Hemophilia A & B Ofitis in Hemophilia A & B

• Ofitlia in Hemophilia A & B

Visit The Spherix Portal





Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at www.clientportal.spherixglobalinsights.com